Skip to main content
. Author manuscript; available in PMC: 2012 Feb 1.
Published in final edited form as: Neuropharmacology. 2010 Nov 5;60(2-3):480–487. doi: 10.1016/j.neuropharm.2010.11.002

Figure 5.

Figure 5

STAT3 phosphorylation following a single icv injection of1 μg of leptin (sold bars) or ACSF (open bars) in rats administered control vector (rAAV-GFP) or rAAV-leptin 451 days earlier. STAT3 phosphorylation was assessed 1 hour later in the indicated brain regions. Immunoblots are provided below each figure. Blot 1 includes samples from control (GFP-treated) rats administered ACSF or leptin along with rAAV-leptin treated rats administered leptin. Blot 2 repeats the control rats administered ACSF and rAAV-leptin treated rats administered ACSF or leptin. Values represent the ratio of P-STAT3 to total STAT3 and are the mean ± SE of 7-8 rats per group. The level of the ACSF injected control for each individual tissue is arbitrarily set to 100 with SE adjusted proportionally with remaining groups normalized to the level in ACSF injected control. P< 00001 for difference with leptin injection (all brain regions); P<0.05 for difference with rAAV-leptin (all brain regions); P<0.0005 for interaction (all brain regions) by two-way ANOVA; Post-hoc analysis: *P <0.001 (P=0.007 for ARC) for difference between leptin and ACSF injection in the rAAV-GFP treated rats. ** P< 0.005 (LH, VMH, DMH) or P<0.05 (ARC, VTA) for difference between leptin and ACSF injection in the rAAV-Leptin treated rats. τ P<0.001 (P<0.007 for ARC) for difference between maximal leptin signaling in rAAV-Leptin and rAAV-GFP.